Dr. Sehgal on the Clinical Implications of CAR T-Cell Therapy in DLBCL

Video

Alison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the clinical implications of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

Alison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the clinical implications of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

The approvals of axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah) have altered the paradigms of relapsed/refractory non-Hodgkin lymphoma and relapsed/refractory DLBCL, respectively. Specifically, these agents have changed the way treatment is approached for patients with DLBCL, says Sehgal. This is particularly true for patients who relapse after autologous stem cell transplant (ASCT), have resistant disease, and those who can’t achieve a remission to even proceed with ASCT, she adds.

Instead of looking to palliative care when patients relapse, patients who are fit enough may instead be able to receive CAR T-cell therapy. Currently, CAR T-cell therapy is not curative, although the goal is to achieve a curative approach, says Sehgal. Therefore, the field is focused on bringing intensive therapy that could lead to long-term remission to patients.

Related Videos
Judy Lieberman, MD, PhD, the endowed chair in cellular and molecular medicine at Boston Children’s Hospital
Alexandra Gomez Arteaga, MD
Paul Harmatz, MD
Mark Walters, MD
Mitchel Horwitz, MD
Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center
Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin
Raj Chovatiya, MD, PhD
Jessica S. Little, MD, a transplant infectious diseases physician at Dana-Farber Cancer Institute
© 2024 MJH Life Sciences

All rights reserved.